Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...

Preclinical models highlight the potential of KT-253 as a monotherapy and combined with the standard of care agent venetoclax for the treatment of Acute Myeloid Leukemia (AML) MDM2 degraders shown to ...

Please provide your email address to receive an email when new articles are posted on . Sandra D’Angelo, MD, discussed initial phase 1A/1B data from a clinical trial on the efficacy and safety of ...

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 Between July 2013 and August 2018, 107 patients were enrolled and received ...

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...

Studying MDM2 inhibitors using Venetoclax (Venclexta) has led to unique responses in patients with acute myeloid leukemia (AML) and warrants wider and further study, according to data presented at the ...

The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with ...

Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness. Fortunately, blindness and eye damage can be prevented by suppressing the immune system ...